Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

According to CDC data, as of January 30, 2021, 25,780,144 individuals residing in the United States had been infected by COVID-19 and 435,151 had died as a result of the disease. No drug has yet been identified that explicitly kills the COVID-19 virus. While various vaccines have been developed to prevent infection, the virus continues to mutate, and scientific research remains behind the virus trajectory.

The human immune system, when functioning properly, can prevent the body from succumbing to infections from external sources and from internal cell mutations, including the COVID-19 virus and cancer cells. That is, the defense system comes from nature. This clinical study proves that the immune system can respond to those antigens and kill them if the immune system is given a chance. However, the human immune system can become compromised through inflammation and subsequently unable to successfully prevent infection and cancer.

When COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over-immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back.

Medical herbs can mediate the immunity disorder caused by infections, and mutated cells, including COVID-19 and its mutations. Our pre-clinical study found that the medical herbs inhibit the inflammation expression, reduce the chance of cytokine-storm, prevent deterioration, and reduce the mortality rate. In addition, the T cells can perform their job when the inflammation is under control. The virus and cancer cells belong to antigens that should be killed by natural killer (NK) cells and T cells. This clinical study aims not to provide drugs to kill the antigens, but rather to create the necessary conditions inside the human body to allow the immune system a chance to overcome the antigens. The clinic has used this treatment concept to successfully treat infected patients and cancer patients.

Inclusion criteria

A subject will be eligible for inclusion in this study if any of the following criteria apply:

• Individuals diagnosed with COVID-19 virus infection in the past 1-20 days must submit the proved metrics of COVID-19 virus marks positive during the registration;
• The age of participants is between 10-70 years old;
• The participants are received or not received conventional medication treatment, and continuing the treatment patients, could be enrolled in this clinical study;
• This clinical study is not restricted to gender, age, sex, race, and nationality;
• The participants must have reports of CBC, C3, C4, IgM, IgG, CD4/CD8, and lungs' images ready before the clinical study;
• The Participants must repeat the evaluation experiment during and at the end of the clinical study.

Exclusion criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

• Individuals with a prior COVID-19 virus infection that no longer shows up from COVID-19 testing;
• Children who are younger than 10-year-old, cannot control themselves to take the medical herbs on time;
• Elders whose age beyond 70-year-old, with severe underline illness;
• COVID-19 virus-infected patients who do not feel willing to take medical herbs;
• Patients diagnosed with COVID-19 virus infection cannot consistently finish the treatment courses for a specific reason;
• Patients diagnosed with COVID-19 virus infection but do not willing to share their information with the public;
• Current or past participation within a specified timeframe in another clinical trial, as warranted by this intervention's administration;
• Severe patients, when there have insufficient normal cells, can be adjusted, with pre-list diseases life-threatening.